Company: PIII
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001140361-25-014596
Chunk: 38

Company: P3 Health Partners Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 38
---
 which is available on our website at ir.p3hp.org, the Compensation and Nominating Committee has the authority to retain or obtain the advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. The Compensation and Nominating Committee did not engage the services of a compensation consultant during 2024. The Compensation and Nominating Committee may delegate its authority under its charter to one or more subcommittees as it deems appropriate from time to time. The Compensation and Nominating Committee may also delegate to an executive officer the authority to grant equity awards to certain employees, as further described in its charter and subject to the terms of our equity plans. The members of our Compensation and Nominating Committee are Lawrence B. Leisure, Thomas E. Price, M.D., Mary Tolan and Greg Wasson. Mary Tolan serves as the Chair of the Compensation and Nominating Committee. Each member of the Compensation and Nominating Committee qualifies as an independent director under Nasdaq’s heightened independence standards for members of a compensation committee. Thomas E. Price, M.D. qualifies as a “non-employee director” as defined in Rule 16b-3 of the Exchange Act. The Compensation and Nominating Committee met five times during the fiscal year ended December 31, 2024. 24 EXECUTIVE COMPENSATION This section discusses the material components of the executive compensation program for our executive officers who are named in the “Summary Compensation Table” below. Historical compensation information does not take into account the Reverse Stock Split. In 2024, the “named executive officers” and their positions were as follows:

| ● | Aric Coffman, M.D., Chief Executive Officer and President; |

| ● | Sherif Abdou, M.D., Former Chief Executive Officer and President; |

| ● | Amir Bacchus, M.D., Chief Medical Officer; |

| ● | Leif Pedersen, Chief Financial Officer; and |

| ● | Atul Kavthekar, Former Chief Financial Officer. |

Summary Compensation Table The following table sets forth information, on a pre-Reverse Stock Split basis, concerning the compensation of the named executive officers for the years ended December 31, 2024 and 2023:

| Name and                    
 Principal                   
 Position                    | ​ |    Year | ​ |  Salary 
     ($) | ​ |     Bonus 
    ($)(1) | ​ |     Stock 
    Awards 
    ($)(2) | ​ |